Drugs / Autologous Conditioned Serum
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03850080 | Oct 2017 → Sep 2018 | osteoarthritis, knee | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06839326 | Nov 2024 → Jun 2025 | osteoarthritis | Batman University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Conditioned Serum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03850080 ↗ |
| Known as | ACS | “This study aims to compare the clinical efficacy of intra-articular applications of platelet-rich plasma (PRP) and autologous conditioned serum (ACS), both derived from the...” NCT06839326 ↗ |
| Route | Other | “1 mL of ACS will be injected into the joint” NCT06839326 ↗ |